Physician profile
Mary J Ciechoski
NPI 1740245992
$199,778.52
in general payments reported to CMS, 2019-2025
39 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $43K · 2023: $42K · 2024: $50K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Food and Beverage: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Consulting Fee: $7,220 · Travel and Lodging: $4,351 · Honoraria: $380 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,692.86 |
| Food and Beverage | $21,637.20 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,885.00 |
| Consulting Fee | $7,220.00 |
| Travel and Lodging | $4,350.98 |
| Honoraria | $380.00 |
| Education | $290.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70,659.09 | 2021-2025 | |
| Janssen Biotech, INC. | $29,312.17 | 2021-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $19,503.15 | 2022-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $17,822.47 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15,268.89 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $9,697.00 | 2021-2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $7,717.45 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $6,821.32 | 2021-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $6,254.52 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $3,430.59 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $3,146.66 | 2022-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $2,116.44 | 2021-2024 | Stelara, Tremfya |
| Eli Lilly and Company | $1,500.00 | 2022 | |
| Novo Nordisk INC | $1,084.96 | 2021-2025 | Wegovy |
| Ardelyx, INC. | $927.41 | 2022-2025 | Ibsrela |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $793.16 | 2021-2025 | |
| Qol Medical, LLC | $604.20 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $485.61 | 2022-2025 | |
| Madrigal Pharmaceuticals | $463.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $308.97 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $246.85 | 2021-2025 | Rebyota |
| Braintree Laboratories, INC. | $187.61 | 2021-2023 | Sutab, Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.93 | 2023-2024 | Cyltezo |
| Alfasigma USA, INC. | $161.62 | 2022 | |
| Aimmune Therapeutics, INC. | $153.89 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $126.63 | 2023-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $109.43 | 2022-2023 | |
| Organon LLC | $107.80 | 2023-2025 | Hadlima, Renflexis |
| Celltrion USA INC. | $100.45 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Daiichi Sankyo INC. | $92.57 | 2021-2024 | Injectafer |
| Sandoz INC. | $86.56 | 2023-2025 | Hyrimoz, Pyzchiva |
| Exact Sciences Corporation | $83.95 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $78.56 | 2022-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $49.46 | 2025 | Iqirvo |
| Teva Pharmaceuticals USA, INC. | $31.69 | 2024 | Simlandi |
| Boston Scientific Corporation | $28.45 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.49 | 2025 | Kristalose |
| Mallinckrodt Hospital Products INC. | $17.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ciechoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.